iRhythm Holdings, Inc.
In the published model solve dated 2026-Q2, anchored at $120.80, iRhythm Holdings, Inc. (IRTC) is priced for +14.5% growth. boothcheck publishes no house fair value, target price, or buy/sell rating; individual model outputs and user-controlled scenarios are analytical inputs, not Boothcheck targets. The narrative was composed June 14, 2026 from SEC EDGAR filings.
• iRhythm sells Zio, an FDA-cleared, 14-day wear-and-mail heart-rhythm patch, at a 70.6% gross margin, and Q1 2026 revenue of $199.4 million grew 25.7% year over year, so this is a fast-growing medical-device franchise that has not yet flipped to GAAP profit. • The biggest risk is the gap between growth and earnings: the company still posts an operating loss, runs on a net cash cushion of about $455 million, and a 2.4% annual rise in share count means the path to profitability has to outrun both
Is IRTC overvalued? See what's priced in →
292 institutional managers reported holding IRTC in 13F filings for the quarter ended 2026-03-31. 36 opened new positions that quarter. Held by Vanguard Group, BlackRock, Millennium Management, among others. On the short side, 2.9M shares were sold short as of the 2026-06-15 count, about 9% of shares outstanding (5.8 days of typical volume to cover).
Quarterly 13F filings arrive up to 45 days after quarter end, so the picture is never current (filed through 2026-05-29). Nothing here is investment advice.
IRTC's share count grew 10.9% over the past five years even with $25.00M spent on repurchases. It pays no dividend. Cash returned over the past three years: $25.00M in repurchases.
Share counts are split-adjusted; repurchase totals are gross of share issuance. Nothing here is investment advice.
Open-market insider buys at IRTC over the trailing three years: 2024: 2 buys totaling $522k. 21 officers and directors are on file.
Code P open-market purchases from SEC Form 4 filings, non-derivative, excluding scheduled 10b5-1 plans. Nothing here is investment advice.
IRTC's recent reports: the day-one move, then what the following quarter actually did.
| report | day one | next quarter |
|---|---|---|
| 2023-08-05 | +13.9% | -27.3% |
| 2023-11-03 | +5.5% | +26.4% |
| 2024-02-23 | -6.1% | +6.5% |
| 2024-05-03 | -8.1% | -3.1% |
Day-one is the close-to-close move around the filing. Nothing here is investment advice.
IRTC's latest 8-K filings: 2026-06-15 (items 1.05); 2026-06-05 (items 7.01, 9.01); 2026-05-28 (items 5.02, 5.07, 9.01); 2026-04-30 (items 2.02, 9.01); 2026-04-01 (items 4.01, 9.01).
Item codes are the SEC's own classification of what each report discloses. Dates link to the filing on EDGAR. Nothing here is investment advice.
Model solve date: 2026-Q2
Narrative composed: June 14, 2026
Each week boothcheck ranks the stocks whose prices are betting on the most. Read the most stretched bets archive →
boothcheck is also on Android. Get the app on Google Play →
For informational and research purposes only. Not investment advice. Not a recommendation to buy, sell, or hold any security. boothcheck is not a registered investment adviser. Past performance does not guarantee future results.